Business Model Breakdown
How Molina Healthcare Inc Makes Money
MOH
Market Cap
$7.3B
Annual Revenue
$40.6B
Profit Margin
0.0%
Employees
18,000
The Short Version
Molina Healthcare Inc. operates as a managed care organization primarily serving individuals and families who receive healthcare through government-sponsored programs such as Medicaid, Medicare, and the state health insurance marketplaces. The company earns revenue by receiving fixed monthly premiums from state and federal governments for each enrolled member. It then manages and pays for the medical services these members receive, with its profitability depending on its ability to effectively manage healthcare costs while providing quality care to its diverse member base.
Where the Revenue Comes From
Government-sponsored Medicaid programs
Medicare Advantage and prescription drug plans
State health insurance marketplaces
Who buys: Individuals and families qualifying for government assistance programs, including low-income families, children, and seniors.
Why It Works (Competitive Advantages)
- ✔Efficient scale in government-sponsored healthcare programs
- ✔Strong relationships with state Medicaid agencies
- ✔Expertise in navigating complex regulatory environments
Economic Moat: Narrow (Cost Advantages, Intangible Assets/IP (regulatory expertise, state contracts))
What Our Analysis Says
DVR Score as of April 9, 2026
Molina Healthcare operates in a mature, highly regulated government-sponsored healthcare market, which fundamentally limits its exponential growth potential. While financially sound, its business model thrives on incremental contract wins and operational efficiency, not disruptive innovation capable of generating 10x growth within 3-5 years. The current market cap of $7.60B makes a tenfold expansion to $76B highly improbable in this timeframe. Recent negative developments, including an ongoing investigation, disappointing FY26 EPS guidance, declining net margins, and analyst downgrades, further underscore the lack of hyper-growth catalysts and introduce significant near-term risks. The stock is down 56% over the past year, reflecting these challenges. There are no material changes that would alter the fundamental assessment of its lack of 10x potential.